Bio-IT World Conference Sessions Present Cloud-Deployed Genedata Screener as Integral to Biotech R&D Infrastructure
Genedata Screener best-of-breed screening data analysis platform now integrated with biotech infrastructure initiative from AWS
May 15, 2018
Boston, MA, USA
Genedata, a leading provider of advanced software solutions for R&D, today announced that the Genedata Screener® platform has become the first in-vitro screening data analysis platform for the new biotech infrastructure initiative from Amazon Web Services (AWS). AWS will unveil its cloud-based Biotech Quick Start program in a presentation at the 2018 Bio-It World Conference. In addition to being among the featured technologies in these programs, other Genedata solutions supporting the R&D workflow will be demonstrated at the Genedata Bio-IT World Conference Booth #521 (Seaport World Trade Center; May 15–17).
Genedata Screener: On-premises or in the Cloud, the Platform of Choice
Pharmaceutical R&D is continually challenged by the integration, analysis and management of all types of data coming from disparate sources ranging from experimental to operational to clinical and more. The Genedata Screener platform successfully addresses these data challenges by effectively capturing, analyzing, visualizing, and managing screening data from in-vitro screening assay technologies across and beyond the enterprise. Handling data from any screening instrument and supporting even very complex and ultra-high throughput experimental set-ups, Genedata Screener is used by the majority of leading pharmaceutical companies, CROs, and academic research institutions worldwide.
Moreover, on-premises or in the cloud, Genedata Screener provides a scalable infrastructure that supports the growth of early-stage biotechs as well as meeting the industrial-grade demands of multi-site/geography enterprises. The AWS Biotech Quick Start is designed to provide an enterprise-grade research environment in the cloud, based on best practices and integrated with leading life science solutions. Emerging from an AWS collaboration with Third Rock Ventures, it aims to remove operational, logistical, and data management bottlenecks with industry-leading tools that accelerate novel drug and scientific discovery.
“Our successful relationship with Third Rock Ventures and AWS is an example of another milestone in our strategy to enable early-stage biotechs to benefit from our innovative software solutions,” noted Dr. Othmar Pfannes, CEO of Genedata. “On Biotech QuickStart, innovative R&D organizations now can quickly get access to Genedata Screener and scale up the use of the software while they scale up their R&D activities. We look forward to supporting more and more organizations to do just this by easy and flexible deployment routes.”
Editorial Notes: Bio-IT World Conference Presentations
Genedata, ChemAxon, and Titian Partner to Deliver Integration Between Registration, Sample Management and Data Analysis
John Munro, Business Account Manager/Genedata; Marcus Oxer, Senior Application Consultant/Titian Software; Norbert Sas, Head, Consultancy Services/ChemAxon
May 15 | 6:20pm – 6:40pm EDT
Third Rock Ventures presentation:
A Reusable Cloud-Based Infrastructure for Growing Biotechs
Karina Chmielewski, Sr. Director, Platform Operations/Third Rock Ventures
May 16 | 11:30am –12:00pm EDT
Amazon Web Services presentation:
Biotech-in-a-Box: Turn-Key Cloud Infrastructure for Enterprise-Grade Research
Elliot Menschik, MD, PhD, Healthcare and Life Science Ventures/Amazon Web Services
May 17 | 12:50pm –1:20pm EDT
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.